Lu Chen1, Yanan Zhang1, Xin Shu1, Qiong Chen1, Tiantian Wei2, Heman Wang1, Xiaorong Wang3, Qirou Wu1, Xiaomei Zhang1, Xiaoyan Liu1, Suya Zheng1, Lan Huang3, Junyu Xiao2, Chao Jiang1, Bing Yang1, Zhiping Wang4, Xing Guo5. 1. Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China. 2. Academy for Advanced Interdisciplinary Studies, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China. 3. Departments of Physiology and Biophysics and of Developmental and Cell Biology, University of California, Irvine, CA, USA. 4. Center for Neuroscience and Department of Neurology of Second Affiliated Hospital, NHC and CAMS Key Laboratory of Medical Neurobiology, Zhejiang University School of Medicine, Hangzhou, China. z4wang@zju.edu.cn. 5. Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China. xguo@zju.edu.cn.
Abstract
Reversible phosphorylation has emerged as an important mechanism for regulating 26S proteasome function in health and disease. Over 100 phospho-tyrosine sites of the human proteasome have been detected, and yet their function and regulation remain poorly understood. Here we show that the 19S subunit Rpt2 is phosphorylated at Tyr439, a strictly conserved residue within the C-terminal HbYX motif of Rpt2 that is essential for 26S proteasome assembly. Unexpectedly, we found that Y439 phosphorylation depends on Rpt2 membrane localization mediated by its N-myristoylation. Multiple receptors tyrosine kinases can trigger Rpt2-Y439 phosphorylation by activating Src, a N-myristoylated tyrosine kinase. Src directly phosphorylates Rpt2-Y439 in vitro and negatively regulates 26S proteasome activity at cellular membranes, which can be reversed by the membrane-associated isoform of protein tyrosine phosphatase nonreceptor type 2 (PTPN2). In H1975 lung cancer cells with activated Src, blocking Rpt2-Y439 phosphorylation by the Y439F mutation conferred partial resistance to the Src inhibitor saracatinib both in vitro and in a mouse xenograft tumor model, and caused significant changes of cellular responses to saracatinib at the proteome level. Our study has defined a novel mechanism involved in the spatial regulation of proteasome function and provided new insights into tyrosine kinase inhibitor-based anticancer therapies.
Reversible phosphorylation has emerged as an important mechanism for regulating 26S proteasome function in health and disease. Over 100 phospho-tyrosine sites of the n class="Species">human proteasome have been detected, and yet their function and regulation remain poorly understood. Here we show that the 19S subunit Rpt2 is phosphorylated at Tyr439, a strictly conserved residue within the C-terminal HbYX motif of Rpt2 that is essential for 26S proteasome assembly. Unexpectedly, we found that Y439 phosphorylation depends on Rpt2 membrane localization mediated by its N-myristoylation. Multiple receptors tyrosine kinases can trigger Rpt2-Y439 phosphorylation by activating Src, a N-myristoylated tyrosine kinase. Src directly phosphorylates Rpt2-Y439 in vitro and negatively regulates 26S proteasome activity at cellular membranes, which can be reversed by the membrane-associated isoform of protein tyrosine phosphatase nonreceptor type 2 (PTPN2). In H1975lung cancer cells with activated Src, blocking Rpt2-Y439 phosphorylation by the Y439F mutation conferred partial resistance to the Src inhibitor saracatinib both in vitro and in a mouse xenograft tumor model, and caused significant changes of cellular responses to saracatinib at the proteome level. Our study has defined a novel mechanism involved in the spatial regulation of proteasome function and provided new insights into tyrosine kinase inhibitor-based anticancer therapies.
Authors: Jared A M Bard; Ellen A Goodall; Eric R Greene; Erik Jonsson; Ken C Dong; Andreas Martin Journal: Annu Rev Biochem Date: 2018-04-13 Impact factor: 23.643
Authors: David M Smith; Shih-Chung Chang; Soyeon Park; Daniel Finley; Yifan Cheng; Alfred L Goldberg Journal: Mol Cell Date: 2007-09-07 Impact factor: 17.970
Authors: Markus R Eisele; Randi G Reed; Till Rudack; Andreas Schweitzer; Florian Beck; Istvan Nagy; Günter Pfeifer; Jürgen M Plitzko; Wolfgang Baumeister; Robert J Tomko; Eri Sakata Journal: Cell Rep Date: 2018-07-31 Impact factor: 9.423
Authors: Soyeon Park; Xueming Li; Ho Min Kim; Chingakham Ranjit Singh; Geng Tian; Martin A Hoyt; Scott Lovell; Kevin P Battaile; Michal Zolkiewski; Philip Coffino; Jeroen Roelofs; Yifan Cheng; Daniel Finley Journal: Nature Date: 2013-05-05 Impact factor: 49.962